ZOETIS DRY COW TUBES STAND UP TO THE COMPETITION. BRAND SPECTRAMAST ® DC* (ceftiofur hydrochloride) Sterile Suspension ALBADRY PLUS ® (penicillin G procaine and novobiocin sodium) Suspension ToMORROW ® Cefa-Dri ® (cephapirin benzathine) Orbenin ® -DC (benzathine cloxacillin) Dry-Clox ® (benzathine cloxacillin) ACTIVE INGREDIENT Ceftiofur 500 mg Penicillin 200,000 IU and novobiocin 400 mg Cephapirin 300 mg Cloxacillin 500 mg Cloxacillin 500 mg INDICATIONS Treatment Treatment of subclinical mastitis Treatment of mastitis Treatment and prophylaxis of mastitis Treatment of mastitis LABELED PATHOGENS Staph. aureus Strep. dysgalactiae Strep. uberis Staph. aureus Strep. agalactiae Staph. aureus Strep. agalactiae Staph. aureus Strep. agalactiae Staph. aureus Strep. agalactiae PRE-SLAUGHTER WITHDRAWAL* 16 days 30 days 42 days 28 days 30 days MILK DISCARD** 0 hours 72 hours 72 hours 0 hours 0 hours DRY PERIOD LENGTH 30 days 30 days 30 days 28 days 30 days AVAILABILITY R x OTC OTC R x R x YEAR INTRODUCED 2005 1983 1978 1975 1975 *After last administration (or treatment) **Milk discard times begin at first milking post freshening and require completion of a minimum dry cow period. DRY COW | MILK QUALITY ***Zero milk discard period after calving following a 30-day dry cow period. KEY FEATURES: • Unique combination of penicillin and novobiocin provides reliable therapy for subclinical mastitis in dry cows • Has a synergistic effect on bacterial isolates from bovine intramammary infections 1 • Bactericidal activity against the two common mastitis- causing pathogens — Staph. aureus and Strep. agalactiae • Helps eliminate single-antibiotic failures and reduces the likelihood of resistance KEY FEATURES: • Attacks more major mastitis-causing pathogens, including Staphylococcus aureus, Streptococcus dysgalactiae and Strep. uberis • Shortest meat withdrawal — allows you to maximize your management options • Zero milk discard*** — so you can get them back in the milking string faster • Greater flexibility in milk and cattle management decisions Important Safety Information: Inappropriate dosage or treatment intervals with SPECTRAMAST DC and/or failure to complete a minimum dry cow period (30 days) may result in violative milk residues. In cows completing a 30-day dry cow period, no milk discard is necessary. Following treatment with SPECTRAMAST DC, a 16-day pre-slaughter withdrawal is required. As with all drugs, SPECTRAMAST DC should not be used in animals found to be hypersensitive to the product. 1 Wheeler SJ, Edmondson PW, et al. Effect of Penicillin/Novobiocin (TETRADELTA ™ Dry Cow, ALBADRY PLUS ® Sterile Suspension) Dry Cow Therapy on Somatic Cell Count of Dairy Cows Over the Dry Period. Proc International Buiatrics Congress 2000. All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. ©2013 Zoetis Inc. All rights reserved. GDR13164 Important Safety Information: Do not use ALBADRY PLUS less than 30 days prior to calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Treated animals must not be slaughtered for food for 30 days following udder infusion. See full Prescribing Information attached.
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
ZOETIS DRY COW TUBESSTAND UP TO THE COMPETITION.
BRAND SPECTRAMAST® DC* (ceftiofur hydrochloride)
Sterile Suspension
ALBADRY PLUS®
(penicillin G procaine and novobiocin sodium)
Suspension
ToMORROW®
Cefa-Dri®
(cephapirin benzathine)
Orbenin®-DC (benzathine cloxacillin)
Dry-Clox®
(benzathine cloxacillin)
ACTivE iNgREDiENT Ceftiofur
500 mgPenicillin 200,000 IU and
novobiocin 400 mg
Cephapirin 300 mg
Cloxacillin 500 mg
Cloxacillin 500 mg
iNDiCATiONS TreatmentTreatment
of subclinical mastitis
Treatment of mastitis
Treatment and prophylaxisof mastitis
Treatmentof mastitis
LABELED PAThOgENS Staph. aureus
Strep. dysgalactiaeStrep. uberis
Staph. aureusStrep. agalactiae
Staph. aureusStrep. agalactiae
Staph. aureusStrep. agalactiae
Staph. aureusStrep. agalactiae
PRE-SLAUghTER WiThDRAWAL*
16 days 30 days 42 days 28 days 30 days
MiLk DiSCARD** 0 hours 72 hours 72 hours 0 hours 0 hours
DRY PERiOD LENgTh
30 days 30 days 30 days 28 days 30 days
AvAiLABiLiTY Rx OTC OTC Rx Rx
YEARiNTRODUCED
2005 1983 1978 1975 1975
*After last administration (or treatment)**Milk discard times begin at first milking post freshening and require completion of a minimum dry cow period.
DRY COW | MiLk QUALiTY
***Zero milk discard period after calving following a 30-day dry cow period.
kEY FEATURES:• Unique combination of penicillin and novobiocin provides
reliable therapy for subclinical mastitis in dry cows• Has a synergistic effect on bacterial isolates from bovine
intramammary infections1
• Bactericidal activity against the two common mastitis- causing pathogens — Staph. aureus and Strep. agalactiae
• Helps eliminate single-antibiotic failures and reduces the likelihood of resistance
kEY FEATURES:• Attacks more major mastitis-causing pathogens, including
Staphylococcus aureus, Streptococcus dysgalactiae and Strep. uberis
• Shortest meat withdrawal — allows you to maximize your management options• Zero milk discard*** — so you can get them back in the
milking string faster• Greater flexibility in milk and cattle management decisions
important Safety information: Inappropriate dosage or treatment intervals with SPECTRAMAST DC and/or failure to complete a minimum dry cow period (30 days) may result in violative milk residues. In cows completing a 30-day dry cow period, no milk discard is necessary. Following treatment with SPECTRAMAST DC, a 16-day pre-slaughter withdrawal is required. As with all drugs, SPECTRAMAST DC should not be used in animals found to be hypersensitive to the product.
1 Wheeler SJ, Edmondson PW, et al. Effect of Penicillin/Novobiocin (TETRADELTA™ Dry Cow, ALBADRY PLUS® Sterile Suspension) Dry Cow Therapy on Somatic Cell Count of Dairy Cows Over the Dry Period. Proc International Buiatrics Congress 2000. All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. ©2013 Zoetis Inc. All rights reserved. GDR13164
important Safety information: Do not use ALBADRY PLUS less than 30 days prior to calving. Milk from treated cows must not be used for food during the first 72 hours after calving. Treated animals must not be slaughtered for food for 30 days following udder infusion. See full Prescribing Information attached.
For I
ntr
amam
mar
y In
fusi
on in
Dry
Dai
ry C
attle
Onl
y
FO
R U
SE
IN A
NIM
AL
S O
NLY
— N
OT
FO
R H
UM
AN
US
E
CA
UT
ION
: Fe
dera
l (US
A) la
w re
stric
ts th
is d
rug
to u
se b
y or
on
the
orde
r of
a
licen
sed
vete
rinar
ian.
DE
SC
RIP
TIO
N:
Cefti
ofur
hy
droc
hlor
ide
is
a ce
phal
ospo
rin
antib
iotic
.
Chem
ical
Stru
ctur
e of
Ce
ftiof
ur H
ydro
chlo
ride
Ch
emic
al N
ame
of
C
efti
ofu
r H
ydro
chlo
rid
e5-
Thia
-1-a
zabi
cycl
o[4.
2.0]
oct-2
-ene
-2-c
arbo
xylic
aci
d, 7
-[[2
-(2-
amno
-4-th
iazo
lyl)-
2-(m
etho
xyim
ino)
acet
yl]a
min
o]-3
-[[(2
-fura
nylc
arbo
nyl)
thio
]met
hyl]-
8-ox
o,
hydr
ochl
orid
e.
Ce
ftiof
ur
Hydr
ochl
orid
e St
erile
Su
spen
sion
is
an
oi
l-bas
ed
ster
ile s
uspe
nsio
n.
Ea
ch 1
0 m
L PL
ASTE
T® Di
spos
able
Syr
inge
Con
tain
s:
Cefti
ofur
Equ
ival
ents
(as
the
hydr
ochl
orid
e sa
lt) ..
......
......
......
......
......
......
......
.500
mg
Mic
rocr
ysta
lline
Wax
......
......
......
......
......
......
......
......
......
......
......
......
......
......
...70
0 m
gLa
brafi
l M 1
944
CS ..
......
......
......
......
......
......
......
......
......
......
......
......
......
......
...50
0 m
gCo
ttons
eed
Oil ..
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
......
q.s.
IND
ICA
TIO
NS
FO
R U
SE
SP
EC
TR
AM
AS
T®
DC
Ce
ftiof
ur
Hydr
ochl
orid
e St
erile
Su
s-pe
nsio
n is
in
dica
ted
for
the
treat
men
t of
su
bclin
ical
m
astit
is
in
dairy
ca
ttle
at
the
time
of
dry
off
asso
ciat
ed
with
S
taph
yloc
occu
s au
reus
, S
trep
toco
ccus
dy
sgal
actia
e, a
nd S
trep
toco
ccus
ub
eris
. S
PE
CT
RA
MA
ST
® D
C C
eftio
fur
Hydr
ochl
orid
e St
erile
Sus
pens
ion
has
been
pr
oven
effe
ctiv
e ag
ains
t Sta
phyl
ococ
cus
aure
us,
Str
epto
cocc
us d
ysga
-la
ctia
e, a
nd S
trep
toco
ccus
ube
ris.
DO
SA
GE
Infu
se o
ne (1
) syr
inge
into
eac
h af
fect
ed q
uarte
r at t
he ti
me
of d
ry o
ff.
DIR
EC
TIO
NS
FO
R U
SIN
G P
LA
ST
ET
® D
ISP
OS
AB
LE
SY
RIN
GE
Th
e sy
ringe
is
de
sign
ed
to
prov
ide
the
choi
ce
of
eith
er
inse
rtion
of
th
e fu
ll ca
nnul
a as
ha
s tra
ditio
nally
be
en
prac
ticed
, or
in
serti
on o
f no
mor
e th
an 1
/8 i
nch
of t
he c
annu
la,
as r
epor
ted
by E
berh
art,
R.J.
, et
. al
. 19
87.
Curre
nt C
once
pts
of B
ovin
e M
astit
is,
3rd
Editi
on,
Natio
nal
Mas
titis
Cou
ncil,
Arli
ngto
n, V
A.
a.
Fu
ll in
sert
ion
: Re
mov
e th
e re
d en
d ca
p by
pul
ling
stra
ight
up
as
show
n.
Gent
ly
inse
rt th
e fu
ll ca
nnul
a in
to
the
teat
ca
nal;
care
fully
infu
se th
e pr
oduc
t.
b.
Par
tial
in
sert
ion
: Re
mov
e th
e re
d en
d ca
p by
pul
ling
stra
ight
up
as
sh
own.
Ge
ntly
in
sert
the
expo
sed
white
tip
in
to
the
teat
ca
nal;
ca
refu
lly in
fuse
the
prod
uct.
AD
MIN
IST
RA
TIO
N
Tr
eatm
ent:
W
ash
teat
s th
orou
ghly
wi
th
warm
wa
ter
cont
aini
ng
a su
itabl
e da
iry
antis
eptic
. Dr
y te
ats
thor
ough
ly.
Milk
ou
t ud
der
com
-pl
etel
y. Us
ing
an
alco
hol
pad
prov
ided
, wi
pe
off
the
end
of
the
affe
c-
ted
teat
us
ing
a se
para
te
pad
for
each
te
at.
Choo
se
the
desi
red
inse
rtion
le
ngth
(fu
ll or
pa
rtial
) an
d in
sert
tip
into
te
at
cana
l; pu
sh
plun
ger
to
disp
ense
en
tire
cont
ents
, m
assa
ge
the
quar
ter
to
dist
ri-
bute
th
e su
spen
sion
in
to
the
milk
ci
ster
n.
Rei
nfe
ctio
n:
After
su
cces
sful
treatm
ent,
rein
fectio
n m
ay
occu
r un
less
good
he
rd
man
agem
ent,
sani
tatio
n,
and
mec
hani
cal
safe
ty
mea
sure
s ar
e pr
actic
ed.
Affe
cted
cow
s sh
ould
be
watc
hed
care
fully
to
dete
ct
recu
rrenc
e of
infe
ctio
n an
d po
ssib
le s
prea
d to
oth
er a
nim
als.
CO
NT
RA
IND
ICA
TIO
NS
As w
ith a
ll dr
ugs,
the
use
of S
PE
CT
RA
MA
ST
® D
C S
teril
e Su
spen
sion
is
cont
rain
dica
ted
in a
nim
als
prev
ious
ly fo
und
to b
e hy
pers
ensi
tive
to th
e dr
ug.
WA
RN
ING
S
Pe
nici
llins
an
d ce
phal
ospo
rins
can
caus
e al
lerg
ic
reac
tions
in
se
n-
sitiz
ed
indi
vidu
als.
To
pica
l ex
posu
res
to
such
an
timic
robi
als,
in
clud
ing
cefti
ofur
, m
ay
elic
it m
ild
to
seve
re
alle
rgic
re
actio
ns
in
som
e in
divi
du-
als.
Re
peat
ed
or
prol
onge
d ex
posu
re
may
le
ad
to
sens
itiza
tion.
Av
oid
dire
ct
cont
act
of
the
prod
uct
with
th
e sk
in,
eyes
, m
outh
an
d cl
othi
ng.
Sens
itiza
tion
of
the
skin
m
ay
be
avoi
ded
by
wear
ing
late
x gl
oves
.Per
sons
wi
th
a kn
own
hype
rsen
sitiv
ity
to
peni
cil-
lin
or
ceph
alos
porin
s sh
ould
av
oid
expo
sure
to
th
is
prod
uct.
In
ca
se
of
acci
dent
al
eye
expo
sure
, flu
sh
with
wa
ter
for
15
min
utes
. In
ca
se
of
acci
dent
al
skin
ex
posu
re,
wash
wi
th
soap
an
d wa
ter.
Rem
ove
cont
amin
ated
cl
othi
ng.
If al
lerg
ic
reac
tion
occu
rs
(e.g
., sk
in
rash
, hiv
es, d
ifficu
lt br
eath
ing)
, see
k m
edic
al a
ttent
ion.
Th
e m
ater
ial
safe
ty
data
sh
eet
cont
ains
m
ore
deta
iled
occu
- pa
tiona
l sa
fety
in
form
atio
n.
To
repo
rt ad
vers
e ef
fect
s in
us
ers,
to
ob
tain
m
ore
info
rmat
ion
or
to
obta
in
a m
ater
ial
safe
ty
data
sh
eet,
call
1-80
0-36
6-52
88.
RE
SID
UE
WA
RN
ING
S
1. M
ilk
take
n fro
m
cows
co
mpl
etin
g a
30-d
ay
dry
cow
pe
riod
may
be
us
ed
for
food
wi
th
no
milk
di
scar
d
due
to c
eftio
fur r
esid
ues.
2. F
ollo
wing
la
bel
use,
no
pr
e-sl
augh
ter
with
draw
al
pe
riod
is
requ
ired
for
neon
atal
ca
lves
bo
rn
from
treate
d co
ws re
gard
less o
f col
ostru
m co
nsum
ptio
n.
3. F
ollo
wing
in
tram
amm
ary
infu
sion
, a
16-d
ay
pre-
slau
ghte
r wi
thdr
awal
pe
riod
is
requ
ired
for
treat
ed
cows
.4.
Use
of
th
is pr
oduc
t in
a
man
ner
othe
r th
an
indi
cated
un
der D
OSAG
E m
ight
resu
lt in
viol
ative
resid
ues.
CL
INIC
AL
MIC
RO
BIO
LO
GY
Cefti
ofur
is
a
broa
d-sp
ectru
m
ceph
alos
porin
an
tibio
tic
that
ex
- er
ts
its
effe
ct
by
inhi
bitin
g ba
cter
ial
cell
wall
synt
hesi
s.
Like
ot
her
ß-la
ctam
an
timic
robi
al
agen
ts,
the
ceph
alos
porin
s in
hibi
t ce
ll wa
ll sy
nthe
sis
by
inte
rferin
g wi
th
the
enzy
mes
es
sent
ial
for
pept
idog
ly-
can
synt
hesi
s.
This
ef
fect
re
sults
in
ly
sis
of
the
bact
eria
l ce
ll an
d ac
coun
ts
for
the
bact
eric
idal
na
ture
of
th
ese
agen
ts.
Cefti
ofur
ha
s de
mon
stra
ted
in
vitr
o ac
tivity
ag
ains
t cl
inic
al
isol
ates
an
d is
o-la
tes
from
di
agno
stic
la
bora
torie
s.
The
resu
lts
of
susc
eptib
il-ity
tes
ting
of t
hese
iso
late
s ag
ains
t ce
ftiof
ur a
re p
rese
nted
in
Tabl
es 1
and
2.
Appr
opria
te re
fere
nce s
train
s wer
e als
o su
scep
tibili
ty te
sted
and
thei
r min
imum
inhi
bi-
tory
con
cent
ratio
n (M
IC) v
alue
s an
d zo
ne o
f inh
ibiti
on w
ith a
30
μg d
isk
are
pres
ente
d in
Tabl
e 4.
Tab
le 1
. Cef
tio
fur
MIC
val
ues
fo
r is
ola
tes
fro
m a
mu
lti-
site
cl
inic
al fi
eld
stu
dy
eval
uat
ing
su
bcl
inic
al m
asti
tis
in
dry
dai
ry c
ow
s in
th
e U
.S. d
uri
ng
200
0
Org
anis
mN
o.
MIC
90*
(μg
/mL
)M
IC r
ang
e(μ
g/m
L)
Sta
phyl
ococ
cus
aure
us30
01.
0≤
0.06
to 2
.0
Str
epto
cocc
us d
ysga
lact
iae
55≤
0.06
≤0.
06 to
>64
.0
Str
epto
cocc
us u
beris
581.
0≤
0.06
to 4
.0
* Th
e M
IC fo
r 90%
of t
he is
olat
es.
Tab
le 2
. Cef
tio
fur
MIC
val
ues
* fo
r m
asti
tis
pat
ho
gen
s
fro
m d
iag
no
stic
lab
ora
tori
es in
th
e U
.S. a
nd
Can
ada
Org
anis
mN
o.
Dat
e is
ola
ted
MIC
90**
(μg
/mL
)M
IC r
ang
e(μ
g/m
L)
Sta
phyl
ococ
cus
aure
us
135
1991
–199
21.
00.
13 to
2.0
1019
931.
00.
25 to
1.0
107
1995
1.0
0.25
to 2
.0
6120
001.
0≤
0.06
to 2
.0Co
agul
ase
(-)
stap
hylo
cocc
i13
920
00–2
001
1.0
≤0.
06 to
2.0
Str
epto
cocc
us
dysg
alac
tiae
1519
91–1
992
1.0
≤0.
06 to
2.0
1519
93≤
0.00
39No
rang
e†
152
1997
–199
90.
250.
25 to
4.0
6420
00≤
0.06
≤0.
06 to
0.5
Str
epto
cocc
us
uber
is
2219
91–1
992
0.5
≤0.
06 to
4.0
1519
930.
03≤0
.003
9 to
0.06
133
1997
–199
90.
50.
5 to
8.0
2020
001.
0<0
.06
to 2
.0
Esc
heric
hia
coli
3919
91–1
992
1.0
0.25
to 1
.0
4019
930.
50.
13 to
1.0
5220
000.
5≤
0.06
to 1
.0
* T
he
abov
e in
vi
tro
data
ar
e av
aila
ble,
bu
t th
eir
clin
ical
si
gnifi
canc
e
is u
nkno
wn.
** T
he M
IC fo
r 90%
of t
he is
olat
es.
† No
rang
e, a
ll is
olat
es y
ield
ed th
e sa
me
valu
e.
Ba
sed
on
phar
mac
okin
etic
, m
ilk
resi
due
and
clin
ical
ef
fect
iven
ess
stud
ies
in d
airy
cat
tle fo
llowi
ng in
tram
amm
ary
infu
sion
of c
eftio
fur a
nd th
e M
IC a
nd
disk
(30
μg)
diff
usio
n da
ta fr
om m
astit
is p
atho
gens
, the
follo
wing
bre
akpo
ints
are
re
com
men
ded
by th
e Cl
inic
al a
nd L
abor
ator
ies
Stan
dard
s In
stitu
te (C
LSI)
(Tab
le 3
).
Tab
le 3
. Cu
rren
t re
com
men
ded
inte
rpre
tive
cri
teri
a
esta
blis
hed
by
CL
SI f
or
ceft
iofu
r fo
r B
ovi
ne
Mas
titi
s
Bo
vin
e M
asti
tis
Org
anis
ms
Dis
k C
on
ten
tZ
on
e d
iam
eter
(m
m)
MIC
bre
akp
oin
t
(μg
/mL
)
SI
RS
IR
Sta
phyl
ococ
cus
aure
us
30 μ
g≥
2118
–20
≤17
≤ 2
.04.
0≥
8.0
Str
epto
cocc
us
dysg
alac
tiae
Str
epto
cocc
us
uber
isS
trep
toco
ccus
ag
alac
tiae
Esc
heric
hia
coli
S –
Susc
eptib
le
I
– In
term
edia
te
R
– R
esis
tant
St
anda
rdize
d pr
oced
ures
re
quire
th
e us
e of
la
bora
tory
co
ntro
l or
gani
sms
for
both
st
anda
rdize
d di
ffusi
on
tech
niqu
es
and
stan
- da
rdize
d di
lutio
n te
chni
ques
. Th
e 30
μg
ce
ftiof
ur
sodi
um
disk
sh
ould
gi
ve
the
follo
wing
zo
ne
diam
eter
s an
d th
e ce
ftiof
ur
sodi
um
stan
dard
re
fere
nce
powd
er
(or
disk
) sh
ould
pr
ovid
e th
e fo
llowi
ng
MIC
va
lues
fo
r the
refe
renc
e st
rain
. The
cef
tiofu
r sod
ium
dis
ks o
r sta
ndar
d re
fere
nce
powd
er is
ap
prop
riate
for c
eftio
fur h
ydro
chlo
ride
(Tab
le 4
).
Tab
le 4
. Acc
epta
ble
qu
alit
y co
ntr
ol r
ang
es f
or
ceft
iofu
r
agai
nst
CL
SI r
eco
mm
end
ed A
mer
ican
Typ
e
Cu
ltu
re C
olle
ctio
n (
AT
CC
) re
fere
nce
str
ain
s
Org
anis
m (
AT
CC
No
.)Z
on
e d
iam
eter
* (m
m)
MIC
ran
ge
(μg
/mL
)
Esc
heric
hia
coli
(259
22)
26 to
31
0.25
to 1
.0
Sta
phyl
ococ
cus
aure
us (2
9213
)—
0.25
to 1
.0
Sta
phyl
ococ
cus
aure
us (2
5923
)27
to 3
1—
Pse
udom
onas
aer
ugin
osa
(278
53)
14 to
18
16.0
to 6
4.0
*All
test
ing
perfo
rmed
usi
ng a
30
μg d
isk.
EF
FE
CT
IVE
NE
SS
The
effe
ctiv
enes
s of
a
sing
le
intra
mam
mar
y (IM
M)
infu
sion
of
ce
ftiof
ur
hydr
ochl
orid
e fo
r th
e tre
atm
ent
of
subc
linic
al
mas
ti-tis
pr
esen
t at
th
e tim
e of
dr
y of
f wa
s de
mon
stra
ted
in
a ra
ndom
-ize
d bl
ock
desi
gn
stud
y. Ni
nete
en
vete
rinar
y in
vest
igat
ors
enro
lled
cows
in
21
herd
s an
d fro
m th
ese
21 h
erds
, 431
cow
s an
d 17
08 q
uarte
rs m
et e
nrol
lmen
t cr
iteria
in th
e st
udy
and
calv
ed w
ithin
a 4
5 to
60
day
perio
d fo
llowi
ng e
nrol
lmen
t. Th
e en
rollm
ent c
riter
ia w
ere
whol
e ud
der
som
atic
cel
l cou
nts
grea
ter
than
400
,000
ce
lls/m
L or
a l
inea
r so
mat
ic c
ell
coun
t sc
ore
grea
ter
than
or
equa
l to
5.
Milk
m
icro
biol
ogic
sa
mpl
es
were
ob
tain
ed
prio
r to
tre
atm
ent
and
at
Days
3
and
5 po
st-c
alvi
ng.
Ther
e we
re
5 tre
atm
ent
grou
ps
incl
u-
ding
a
nega
tive
cont
rol
grou
p.
Ther
e we
re
43
cows
in
th
e ne
gativ
e co
ntro
l gr
oup
and
51
cows
in
th
e 50
0 m
g ce
ftiof
ur
grou
p th
at
had
a po
sitiv
e pr
e-tre
atm
ent
milk
cu
lture
th
at
were
ev
alua
ted
for
treat
-m
ent
succ
ess.
Th
e pr
imar
y de
cisi
on
varia
ble
was
the
mic
robi
olog
ic
(ther
apeu
tic)
cure
in
wh
ich
bact
eria
is
olat
ed
pre-
treat
men
t we
re
abse
nt fr
om b
oth
post
-trea
tmen
t sam
ples
.
In
an
othe
r st
udy
in
elev
en
stud
y he
rds,
44
6 co
ws
with
a
so-
mat
ic
cell
coun
t (S
CC)
grea
ter
than
or
eq
ual
to
400,
000
cells
/mL
or
a lin
ear
scor
e gr
eate
r th
an
or
equa
l to
5
were
en
rolle
d.
Cows
wi
th
a dr
y pe
riod
of a
t lea
st 4
5 da
ys w
ere
bloc
ked
by la
ctat
ion
(1st
+ 2
nd o
r ≥3r
d). A
sin
gle
quar
ter m
ilk sa
mpl
e was
asep
tical
ly o
btai
ned
from
all f
our q
uarte
rs fo
r bac
teria
l cul
ture
pr
ior t
o tre
atm
ent a
nd o
n Da
ys 3
and
5 p
ost-c
alvi
ng. T
here
wer
e 4
treat
men
t gro
ups
incl
udin
g a
nega
tive
cont
rol.
Ther
e we
re 8
4 co
ws in
the
nega
tive
cont
rol a
nd 7
3 in
th
e 50
0 m
g ce
ftiof
ur g
roup
that
had
a p
ositi
ve p
re-tr
eatm
ent m
ilk c
ultu
re th
at w
ere
eval
uate
d fo
r tre
atm
ent s
ucce
ss. T
he p
rimar
y de
cisi
on v
aria
ble
was
the
mic
robi
olog
ic
(ther
apeu
tic) c
ure i
n wh
ich
bact
eria
isol
ated
pre
-trea
tmen
t wer
e abs
ent f
rom
bot
h po
st-
treat
men
t sam
ples
.
Ce
ftiof
ur
was
foun
d to
be
ef
fect
ive
agai
nst
Sta
phyl
ococ
cus
au-
reus
, S
trep
toco
ccus
dy
sgal
actia
e,
and
Str
epto
cocc
us
uber
is,
when
co
mpa
red
to
nega
tive
cont
rols
. Th
is
intra
mam
mar
y ce
ftiof
ur
form
ula-
tio
n wa
s we
ll to
lera
ted.
No
adve
rse
form
ulat
ion
rela
ted
even
ts w
ere
note
d du
ring
the
entir
e st
udy.
A la
rge
mul
ti-lo
catio
n fie
ld d
ose
confi
rmat
ion
stud
y an
d a
pilo
t stu
dy
dem
onst
rate
d th
at 5
00 m
g of
cef
tiofu
r inf
used
onc
e pe
r qua
rter a
t the
tim
e of
dry
off
was e
ffect
ive f
or th
e tre
atm
ent o
f sub
clin
ical
mas
titis
in d
airy
cattl
e at t
he ti
me o
f dry
off.
AN
IMA
L S
AF
ET
Y
An
udd
er ir
ritat
ion
stud
y wa
s co
nduc
ted
in 2
2 he
alth
y la
ctat
ing
dairy
cow
s to
as
sess
udd
er ir
ritat
ion
follo
wing
a s
ingl
e in
tram
amm
ary
infu
sion
of a
ste
rile
oil-b
ased
su
spen
sion
con
tain
ing
500
mg
of c
eftio
fur i
nto
all f
our q
uarte
rs fo
llowe
d by
milk
-out
12
hou
rs la
ter.T
hrou
ghou
t the
10
day
post
-trea
tmen
t obs
erva
tion
perio
d th
ere
was
a cl
inic
ally
in
sign
ifica
nt
rise
in
SCC
to
mea
n le
vels
<2
00,0
00
cells
/mL
from
th
e pr
e-in
fusi
on
leve
l of
<6
9,00
0 ce
lls/m
L.
No
clin
ical
si
gns
of
ud-
der
irrita
tion
(swe
lling
, pa
in,
or
redn
ess)
, ch
ange
s in
re
ctal
te
m-
pera
ture
, or c
hang
es in
milk
pro
duct
ion
were
not
ed in
this
stud
y. Cl
inic
al o
bser
vatio
ns
were
mad
e du
ring
a GL
P re
sidu
e de
plet
ion
stud
y of
36
cows
follo
wing
a s
ingl
e in
tra-
mam
mar
y in
fusi
on o
f a s
teril
e oi
l-bas
ed s
uspe
nsio
n co
ntai
ning
500
mg
of c
eftio
fur
into
all
four
qua
rters
at t
he e
nd o
f lac
tatio
n. N
o re
port
of u
dder
irrit
atio
n or
adv
erse
re
actio
n wa
s no
ted
in th
e da
ily v
isua
l obs
erva
tions
ove
r th
e 14
day
s im
med
iate
ly
follo
wing
trea
tmen
t. Co
llect
ivel
y, th
ese
stud
ies
dem
onst
rate
that
the
intra
mam
mar
y in
fusi
on o
f an
oil-b
ased
ste
rile
susp
ensi
on c
onta
inin
g 50
0 m
g of
cef
tiofu
r onc
e in
to
all f
our q
uarte
rs a
t the
end
of l
acta
tion
is c
linic
ally
saf
e an
d no
n-irr
itatin
g to
the
udde
r of
non
-lact
atin
g da
iry c
ows.
MIL
K A
ND
TIS
SU
E R
ES
IDU
E D
EP
LE
TIO
N
A
met
abol
ism
stu
dy in
cat
tle u
sing
rad
iola
bele
d ce
ftiof
ur p
rovi
ded
the
data
to
esta
blis
h to
lera
nces
for c
eftio
fur-r
elat
ed re
sidu
es (a
s de
sfur
oylc
eftio
fur)
in ti
ssue
and
m
ilk. T
hese
tole
ranc
es o
f cef
tiofu
r res
idue
s are
0.1
ppm
in m
ilk, 0
.4 p
pm in
kidn
ey, 2
.0
ppm
in li
ver a
nd 1
.0 p
pm in
mus
cle.
Pi
vota
l re
sidu
e de
clin
e st
udie
s we
re c
ondu
cted
to
asse
ss t
he d
eple
tion
of
cefti
ofur
-rel
ated
resi
dues
, mea
sure
d as
des
furo
ylce
ftiof
ur u
sing
the
offic
ial a
naly
tical
m
etho
d, in
tiss
ues
of tr
eate
d co
ws, i
n m
ilk fr
om tr
eate
d co
ws, a
nd in
tiss
ues
of c
alve
s bo
rn to
trea
ted
cows
. In
thes
e st
udie
s, n
onm
astit
ic c
ows
rece
ived
500
mg
of c
eftio
fur
per
quar
ter
into
all
four
qua
rters
onc
e at
dry
off.
The
milk
res
idue
dep
letio
n st
udy
dem
onst
rate
d th
at m
ilk p
rodu
ced
at ca
lvin
g m
ay b
e use
d fo
r hum
an co
nsum
ptio
n wi
th
no d
isca
rd p
erio
d wh
en th
e tre
atm
ent t
o ca
lvin
g in
terv
al is
30
days
or m
ore.
The
tiss
ue
depl
etio
n st
udy
mea
sure
d re
sidu
es in
the
tissu
es o
f tre
ated
cow
s an
d in
the
tissu
es o
f ne
onat
al c
alve
s bo
rn to
trea
ted
cows
. In
neon
atal
cal
ves
born
to tr
eate
d co
ws, t
issu
e re
sidu
es w
ere l
ess t
han
the c
odifi
ed to
lera
nces
for k
idne
y, liv
er an
d m
uscl
e. T
hese
dat
a su
ppor
t a z
ero
day
pre-
slau
ghte
r with
draw
al p
erio
d fo
r cal
ves
born
to tr
eate
d co
ws
when
the
treat
men
t to
calv
ing
inte
rval
is 3
0 da
ys o
r m
ore,
reg
ardl
ess
of c
olos
trum
co
nsum
ptio
n. T
he ti
ssue
resi
due
depl
etio
n da
ta s
uppo
rt a
16-d
ay p
re-s
laug
hter
with
-dr
awal
per
iod
follo
wing
intra
mam
mar
y in
fusi
on fo
r tre
ated
cow
s.
STO
RA
GE
CO
ND
ITIO
NS
Stor
e at
con
trolle
d ro
om te
mpe
ratu
re 2
0° to
25°
C (6
8° to
77°
F).
Prot
ect f
rom
lig
ht. S
tore
pla
stet
s in
car
ton
until
use
d.
HO
W S
UP
PL
IED
SP
EC
TR
AM
AS
T® D
C S
teril
e Sus
pens
ion
is av
aila
ble i
n ca
rtons
cont
aini
ng
1 un
brok
en p
acka
ge o
f 12–
10 m
L PL
ASTE
T® D
ispo
sabl
e Syr
inge
s with
12
indi
vidu
ally
wr
appe
d 70
% i
sopr
opyl
alc
ohol
pad
s an
d in
pai
ls c
onta
inin
g 12
unb
roke
n pa
ckag
es o
f 12-
10 m
L PL
ASTE
T® D
ispo
sabl
e Sy
ringe
s wi
th 1
44 i
ndiv
idua
lly
wra
pped
70%
isop
ropy
l alc
ohol
pad
s.
NA
DA
# 14
1-23
9, A
pp
rove
d b
y F
DA
www.
spec
tram
ast.c
om o
r cal
l 1-8
00-7
33-5
500
Revi
sed
Dece
mbe
r 200
6 81
9 77
1 00
5
69
1273
Dis
card
Em
pty
Co
nta
iner
: D
O N
OT
RE
US
EK
EE
P O
UT
OF
RE
AC
H O
F C
HIL
DR
EN
SP
EC
TR
AM
AS
T®
DC
bra
nd
of
ceft
iofu
r h
ydro
chlo
rid
e
ster
ile s
usp
ensi
on
Mad
e in
Fra
nce.
AL
BA
DR
Y P
LU
S® S
usp
ensi
on
ND
C 0
009-
3139
-06,
ND
C 0
009-
3139
-02
bra
nd
of p
enic
illin
G p
roca
ine
and
n
ovo
bio
cin
so
diu
m s
usp
ensi
on
Fo
r th
e Tr
eatm
ent o
f Su
bcl
inic
al M
astit
is in
Dry
Cow
s
Fo
r U
dder
Inst
illat
ion
in D
ry C
ows
On
ly
FO
R U
SE
IN A
NIM
AL
S O
NLY
— N
OT
FO
R H
UM
AN
US
E
Res
tric
ted
Dru
g —
Use
On
ly a
s D
irec
ted
(Cal
iforn
ia)
DE
SC
RIP
TIO
N
Eac
h 1
0 m
L P
LA
ST
ET
® D
isp
osa
ble
Syr
ing
e co
nta
ins:
Nov
obio
cin
sodi
um e
quiv
. to
novo
bioc
in ..
......
......
......
......
.....
400
mg
Pen
icill
in G
pro
cain
e ...
......
......
......
......
......
......
......
......
.....
200,
000
IUC
hlor
obut
anol
anh
ydro
us
(chl
oral
der
ivat
ive—
used
as
a pr
eser
vativ
e) ...
50
mg
in a
spe
cial
blan
d ve
hicl
e M
anuf
actu
red
by a
non
-ste
riliz
ing
proc
ess.
IND
ICA
TIO
NS
FO
R U
SE
ALB
AD
RY
PLU
S S
uspe
nsio
n is
ind
icat
ed f
or t
he t
reat
men
t, in
dry
co
ws
only
, of
sub
clin
ical
mas
titis
cau
sed
by s
usce
ptib
le s
trai
ns o
f S
taph
yloc
occu
s au
reus
and
Str
epto
cocc
us a
gala
ctia
e.
WA
RN
ING
S 1
. Do
not u
se le
ss th
an 3
0 da
ys p
rior
to c
alvi
ng.
2. M
ilk fr
om tr
eate
d co
ws
mus
t not
be
used
for
food
dur
ing
the
first
72
hou
rs a
fter
calv
ing.
3. T
reat
ed a
nim
als
mus
t no
t be
sla
ught
ered
for
foo
d fo
r 30
day
s fo
llow
ing
udde
r in
fusi
on.
PR
EC
AU
TIO
NS
Adm
inis
trat
ion
of th
is p
rodu
ct in
any
man
ner o
ther
than
sho
wn
unde
r D
OS
AG
E m
ay r
esul
t in
drug
res
idue
s.
DO
SA
GE
Infu
se o
ne t
ube
per
quar
ter
at s
tart
of
dry
perio
d (b
ut n
ot le
ss t
han
30 d
ays
prio
r to
cal
ving
).
Sh
ake
Wel
l Bef
ore
Usi
ng
DIR
EC
TIO
NS
FO
R U
SIN
G T
HE
FL
EX
I-TU
BE
® S
YS
TE
MT
he F
LEX
I-T
UB
E is
des
igne
d to
pro
vide
the
choi
ce o
f eith
er in
sert
ion
of th
e fu
ll ca
nnul
a, a
s ha
s tr
aditi
onal
ly b
een
prac
ticed
, or i
nser
tion
of
no m
ore
than
1 ⁄8 i
nch
of th
e ca
nnul
a, a
s re
com
men
ded
by th
e N
atio
nal
Mas
titis
Cou
ncil.
a. F
ull
Inse
rtio
n:
Rem
ove
the
blue
end
cap
by
pulli
ng s
trai
ght
up.
Gen
tly in
sert
the
ful
l can
nula
into
the
tea
t ca
nal;
care
fully
infu
se
the
prod
uct.
b. P
arti
al I
nse
rtio
n:
Rem
ove
both
the
blu
e en
d ca
p an
d th
e re
d ca
nnul
a by
pus
hing
sid
eway
s. G
ently
inse
rt th
e ex
pose
d bl
ue ti
p in
to th
e te
at c
anal
; car
eful
ly in
fuse
the
prod
uct.
AD
MIN
IST
RA
TIO
NA
t th
e tim
e of
dry
ing
off,
but
not
less
tha
n 30
day
s pr
ior
to c
alvi
ng,
milk
the
udde
r dr
y. W
ash
the
teat
s an
d ud
der
thor
ough
ly w
ith w
arm
w
ater
con
tain
ing
a su
itabl
e da
iry a
ntis
eptic
. Dry
the
teat
s an
d ud
der
tho
rou
gh
ly.
Infu
se e
ach
qu
art
er
usi
ng
th
e f
ollo
win
g p
roce
du
re.
Usi
ng th
e al
coho
l pad
s pr
ovid
ed, s
crub
eac
h te
at e
nd c
lean
usi
ng a
se
para
te p
ad fo
r ea
ch t
eat.
War
m A
LBA
DR
Y P
LUS
Sus
pens
ion
to
body
tem
pera
ture
and
sha
ke th
orou
ghly
. Cho
ose
the
desi
red
inse
rtio
n le
ngth
(ful
l or p
artia
l) an
d in
sert
tip
into
teat
can
al. I
nstil
l ent
ire c
onte
nts
into
the
quar
ter.
Mas
sage
the
udde
r af
ter
trea
tmen
t to
dist
ribut
e th
e A
LBA
DR
Y P
LUS
Sus
pens
ion
thro
ugho
ut th
e qu
arte
rs. U
sing
a s
uita
ble
teat
dip
, dip
all
teat
s fo
llow
ing
trea
tmen
t.
Dis
card
Em
pty
Con
tain
er; D
O N
OT
RE
-US
E
KE
EP
OU
T O
F R
EA
CH
OF
CH
ILD
RE
N
STO
RA
GE
CO
ND
ITIO
NS
Sto
re a
t con
trol
led
room
tem
pera
ture
20°
to 2
5°C
(68
° to
77°
F)
[see
U
SP
].
HO
W S
UP
PL
IED
ALB
AD
RY
PLU
S S
uspe
nsio
n is
ava
ilabl
e in
unb
roke
n pa
ckag
es o
f 12
-10
mL
PLA
ST
ET
Dis
posa
ble
Syr
inge
s w
ith 1
2 in
divi
dual
ly w
rapp
ed
70%
isop
ropy
l alc
ohol
pad
s an
d un
brok
en p
acka
ges
of 1
44-1
0 m
L P
LAS
TE
T D
ispo
sabl
e S
yrin
ges
with
144
indi
vidu
ally
wra
pped
70%
is
opro
pyl a
lcoh
ol p
ads.
For
a co
py o
f th
e M
ater
ial S
afet
y D
ata
She
et (
MS
DS
) or
to
repo
rt
adve
rse
reac
tions
cal
l Pfiz
er A
nim
al H
ealth
at 1
-800
-366
-528
8.
NA
DA
#55
-098
, Ap
pro
ved
by
FD
AM
ade
in th
e U
nite
d K
ingd
om fo
r
By
Nor
broo
k La
bora
torie
s Li
mite
d N
ewry
, BT
35 6
JP, N
orth
ern
Irel
and
Rev
ised
Dec
embe
r 19
99
812
404
007
Related Documents
